Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 7, 1996, Pages 574-579

  Snoeck, R ^a   Andrei, G ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; DRUG SENSITIVITY; EMBRYO; FETUS LUNG; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0029762282     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01709366     Document Type: Article

References (25)

1. Laskin OL, Stahl-Baylis CM, Kaiman CM, Rosecan LR: Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. Journal of Infectious Diseases 1987, 155: 323-327.
2. Mills J, Jacobson MA, O'Donnell JJ, Cederberg D, Holland GN: Treatment of cytomegalovirus retinitis in patients with AIDS. Reviews of Infectious Diseases 1988, 10, Supplement 3: 522-531.
3. Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, Gordon SM, Owen WF Jr, Matthews TR, Buhles WC, DeArmond B: Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. Journal of Infectious Diseases 1991, 163: 716-719.
4. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC: Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. New England Journal of Medicine 1989, 320: 289-293.
5. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK: Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrobial Agents and Chemotherapy 1991, 35: 2191-2197.
6. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D: Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. Journal of Infectious Diseases 1991, 163: 1348-1351.
7. Palestine AG, Polis MA, De Smet MD, Baird BF, Falloon J, Kovac JA: A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Annals of Internal Medicine 1991, 115: 665-673.
8. Sullivan V, Coen DM: Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. Journal of Infectious Diseases 1991, 164: 781-784.
9. Knox KK, Drobyski WR, Carrigan DR: Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 1991, 337: 1292-1293.
10. De Clercq E: Therapeutic potential of HPMPC as an antiviral drug. Reviews in Medical Virology 1993, 3: 85-96.
11. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A: (S)-1(3-hydroxy-2-phosphonylmethoxyprophyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy 1988, 32: 1839-1844.
12. Neyts J, Snoeck R, Schols D, Baizarini J, De Clercq E: Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 1990, 179: 41-50.
13. Neyts J, Balzarini J, Naesens L, De Clercq E: Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medical Virology 1992, 37: 67-71.
14. Drew WL, Lalezari JR Glutzer E, Lynch T, Flaherty J, Martin JC, Fisher PE, Jaffe HS: The safety, pharmacokinetics, and anti-CMV activity of weekly HPMPC in HIV positive patients excreting CMV. In: Michelson S, Plotkin S (ed): Multidisciplinary approach to understanding cytomegalovirus disease. Excerpta Medica, Elsevier, Amsterdam, 1993, p. 287-292.
15. Andrei G, Snoeck R, Schols D, Goubau P, Desmyter J, De Clercq E: Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. European Journal of Clinical Microbiology & Infectious Diseases 1991, 10: 1026-1033.
16. Littler E, Stuart AD, Chee MS: Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992, 358: 160-164.
17. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK: A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992, 358: 162-164.
18. Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Pozzi LM, Coen DM: A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrobial Agents and Chemotherapy 1993, 37: 19-25.
19. Lurain NS, Thompson KD, Holmes EW, Read GS: Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. Journal of Virology 1992, 66: 7146-7152.
20. Lurain NS, Spafford LS, Thompson KD: Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. Journal of Virology 1994, 68: 4427-4431.
21. Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK, Furione M, Bono F, Palu G, Gerna G: Athreenucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. Journal of Virology 1995, 69: 796-800.
22. Andrei G, Snoeck R, De Clercq E: Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrobial Agents and Chemotherapy 1995, 39: 1632-1635.
23. Coen DM: General aspects of virus drug resistance with special reference to herpes simplex virus. Journal of Antimicrobial Chemotherapy 1986, 18, Supplement B: 1-10.
24. Biron KK, Fyfe JA, Stanat SC, Leslie LK, Sorrell JB, Lambe CU, Coen DM: A human cytomegalovirus mutant resistant to the nucleoside analog 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proceedings of the National Academy of Sciences of the USA 1986, 83: 8769-8773.
25. Tatarowicz WA, Lurain NS, Thompson KD: A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. Journal of Infectious Diseases 1992, 166: 904-907.